Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Beyond Progression in HER2+ Metastatic Breast Cancer
NCT00885755Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2009
- Primary completion
- Feb 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Roche. Primary endpoints: Progression Free Survival (PFS) by Biomarker (Part I) up to 46 months, Progression Free Survival (PFS) by Biomarker (Part II) up to 46 months and 4 more. Started Aug 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00885755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885755.